These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 29778532)

  • 1. Non-alcoholic fatty liver disease: Insights from sphingolipidomics.
    Montefusco DJ; Allegood JC; Spiegel S; Cowart LA
    Biochem Biophys Res Commun; 2018 Oct; 504(3):608-616. PubMed ID: 29778532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover.
    Simon J; Ouro A; Ala-Ibanibo L; Presa N; Delgado TC; Martínez-Chantar ML
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the Sphingolipidome in NAFLD.
    Montefusco D; Lambert J; Anderson A; Allegood J; Cowart LA
    Methods Mol Biol; 2022; 2455():279-303. PubMed ID: 35213002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingolipids at the Crossroads of NAFLD and Senescence.
    Nikolova-Karakashian M
    Adv Cancer Res; 2018; 140():155-190. PubMed ID: 30060808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
    Wang K; Wei Y; Xu R; Li Y; Mao C
    Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis.
    Musso G; Cassader M; Paschetta E; Gambino R
    Gastroenterology; 2018 Aug; 155(2):282-302.e8. PubMed ID: 29906416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingolipid metabolism in non-alcoholic fatty liver diseases.
    Régnier M; Polizzi A; Guillou H; Loiseau N
    Biochimie; 2019 Apr; 159():9-22. PubMed ID: 30071259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of constant light exposure on sphingolipidomics and progression of NASH in high-fat-fed rats.
    Yue F; Xia K; Wei L; Xing L; Wu S; Shi Y; Lam SM; Shui G; Xiang X; Russell R; Zhang D
    J Gastroenterol Hepatol; 2020 Nov; 35(11):1978-1989. PubMed ID: 32027419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease.
    Zhu C; Huai Q; Zhang X; Dai H; Li X; Wang H
    Int J Biol Sci; 2023; 19(1):311-330. PubMed ID: 36594091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Lipid Species Linked to the Progression of Non-Alcoholic Fatty Liver Disease.
    Kawano Y; Nishiumi S; Saito M; Yano Y; Azuma T; Yoshida M
    Curr Drug Targets; 2015; 16(12):1293-300. PubMed ID: 25850622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stable Isotope-Labeled Lipidomics to Unravel the Heterogeneous Development Lipotoxicity.
    Shih LM; Tang HY; Lynn KS; Huang CY; Ho HY; Cheng ML
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30400243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bile acids and sphingolipids in non-alcoholic fatty liver disease.
    Jackson KG; Way GW; Zhou H
    Chin Med J (Engl); 2022 May; 135(10):1163-1171. PubMed ID: 35788089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
    Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
    Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update.
    Hliwa A; Ramos-Molina B; Laski D; Mika A; Sledzinski T
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34199035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD.
    Mashek DG
    Mol Metab; 2021 Aug; 50():101115. PubMed ID: 33186758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A lipidomic approach to bisphenol F-induced non-alcoholic fatty liver disease-like changes: altered lipid components in a murine model.
    Wang X; Wu L; Tao J; Ye H; Wang J; Gao R; Liu W
    Environ Sci Pollut Res Int; 2023 Nov; 30(52):112644-112659. PubMed ID: 37837594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers.
    Sa R; Zhang W; Ge J; Wei X; Zhou Y; Landzberg DR; Wang Z; Han X; Chen L; Yin H
    J Mol Cell Biol; 2016 Jun; 8(3):195-206. PubMed ID: 26993042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin E alleviates non-alcoholic fatty liver disease in phosphatidylethanolamine N-methyltransferase deficient mice.
    Presa N; Clugston RD; Lingrell S; Kelly SE; Merrill AH; Jana S; Kassiri Z; Gómez-Muñoz A; Vance DE; Jacobs RL; van der Veen JN
    Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):14-25. PubMed ID: 30300671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.